VICTORIA, April 9, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
PINK: IPATF) is pleased to announce the extension of its
collaboration with TetraGenetics, a biopharmaceutical company
developing novel therapeutics for autoimmune diseases. The alliance
is focused on the discovery of novel human monoclonal antibodies
against three undisclosed therapeutically-relevant
ion-channels.
"We are pleased to work with ImmunoPrecise, utilizing their
customized phage library technology," said Douglas Kahn, TetraGenetics Chairman and CEO.
"We expect our unique ion channel screening tools to enable deep
mining of ImmunoPrecise's patient library repertoire to identify
rare and functional monoclonal antibodies that we can develop as
therapeutics"
This multi-target service agreement is the result of a
successful research collaboration, utilizing ModiQuests' natural
human phage library repertoire combined with TetraGenetics' unique
ion channel screening tools, in which a multitude of potent
pre-clinical lead antibodies were discovered.
"TetraGenetics' unique capability to generate high
concentrations of difficult-to-produce ion channel proteins caught
our attention," said Jennifer Bath,
CEO of ImmunoPrecise. "TetraGenetics will provide us with unique
screening formulations which should be highly effective for
antibody discovery with our proprietary libraries. We're look
forward to a close collaboration with TetraGenetics, and are
excited by the potential of combining the two unique
technologies."
Ted Clark, Chief Scientific
Officer and Founder of TetraGenetics added, "Combining
TetraGenetics and ImmunoPrecise proprietary technologies is likely
to lead to the discovery of novel therapeutic antibodies to
previously intractable targets for a variety of unmet medical
needs. We're eager to expand this collaboration"
About TetraGenetics
TetraGenetics is focused on the discovery and development of
first-in-class biologic medicines for autoimmune diseases, oncology
and pain. The company has the leading drug discovery platform
(TetraExpress™) for identifying antibodies targeting ion channels
and other transmembrane proteins. TetraGenetics establishes
collaborative partnerships with major biotech companies for
antibody drug discovery and is also actively developing its own
proprietary drug pipeline. For more information, please
visit: www.tetragenetics.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located at the Vancouver Island Technology Park
in Victoria, British
Columbia, in collaboration with its wholly-owned subsidiary
operations at U-Protein Express B.V., in the Life Science
Incubator, Utrecht, and ModiQuest Research, Oss, both
in the Netherlands. The
Company operates globally to offer antibody services from target
analysis to pre-clinical studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B-cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by ImmunoPrecise target a wide variety of therapeutic,
diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.